Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Fineline Cube May 15, 2026
Company Drug

Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma

Fineline Cube May 15, 2026
Company Drug

BeiGene’s Brukinsa Secures Additional EU Approval for Follicular Lymphoma Treatment

Fineline Cube Nov 20, 2023

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has achieved its latest global approval for...

Company Deals

WuXi Biologics’ Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange

Fineline Cube Nov 20, 2023

WuXi Biologics (HKG: 2269) has successfully spun off its conjugate drug-focused subsidiary, WuXi XDC Cayman...

Company Deals

Winning Health Partners with Shanghai Seventh People’s Hospital on Medical AI Services

Fineline Cube Nov 20, 2023

Shanghai-based medical information industry player, Winning Health (SHE: 300253), has announced a partnership with Shanghai...

Company Deals

Thermo Fisher Scientific Expands Partnership with Sangon Biotech to Include GC/MS

Fineline Cube Nov 20, 2023

US-based life sciences giant Thermo Fisher Scientific Inc., (NYSE: TMO) has announced an expansion of...

Company Deals

Usynova Pharmaceuticals Inks Licensing Deal with AstraZeneca for KRASG12D Inhibitor UA022

Fineline Cube Nov 20, 2023

Shanghai-based Usynova Pharmaceuticals Ltd has announced a licensing agreement with UK pharmaceutical major AstraZeneca (AZ,...

Company Drug

Ascentage Pharma Secures Additional Indication Approval for Olverembatinib from NMPA

Fineline Cube Nov 20, 2023

China-based Ascentage Pharma (HKG: 6855) has announced receiving another indication approval from the National Medical...

Company

Aurobindo Pharma’s China Plant Secures EU GMP Approval, Eyes Revenue Generation

Fineline Cube Nov 20, 2023

India-based Aurobindo Pharma reportedly received EU GMP approval for its China-based manufacturing plant last week,...

Company Drug

CSPC Pharmaceutical Group Receives NMPA Approval for Phase II Clinical Study of ALMB-0168

Fineline Cube Nov 20, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Company Drug

Apollomics’ Partner Avistone Wins Conditional Approval for c-Met Inhibitor in China

Fineline Cube Nov 20, 2023

US-based biotech Apollomics Inc., (NASDAQ: APLM) has announced that its Chinese partner, Beijing Avistone Pharmaceuticals...

Company Drug

Fosun Pharmaceutical Secures Clinical Trial Approvals for VT-101 in China and the US

Fineline Cube Nov 20, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced receiving clinical trial approvals for...

Policy / Regulatory

National Reimbursement Drug List Negotiations and Bidding Process Conclude

Fineline Cube Nov 20, 2023

The on-site negotiation and bidding processes for the 2023 update to China’s National Reimbursement Drug...

Company Medical Device

Beijing Balance Medical Technology’s Transcatheter Aortic Valve System Accepted for NMPA Review

Fineline Cube Nov 20, 2023

China’s Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has announced that the National Medical...

Company Deals

Amgen Partners with PostEra for Small-Molecule Drug Discovery Initiative

Fineline Cube Nov 20, 2023

Biopharmaceutical company Amgen (NASDAQ: AMGN) has entered into a drug discovery collaboration with US-based PostEra,...

Company Deals

Baheal Pharmaceutical Group Enters Commercialization Partnership with Guangdong Ruidio Technology

Fineline Cube Nov 20, 2023

China-based health services and distribution giant Baheal Pharmaceutical Group has struck a commercialization partnership with...

Company Drug

Pfizer and Astellas Pharma Secure FDA Approval for Xtandi in High-Risk Non-Metastatic Prostate Cancer

Fineline Cube Nov 20, 2023

Partners Pfizer (NYSE: PFE) and Astellas Pharma (TSE: 4503) last week received indication extension approval...

Company Drug

Yifan Pharmaceutical’s Subsidiary Receives FDA Approval for Ryzneuta (F-627)

Fineline Cube Nov 20, 2023

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary, Evive Biotech Ltd.,...

Company Drug

AstraZeneca Receives FDA Approval for Truqap in HR-Positive, HER2-Negative Breast Cancer

Fineline Cube Nov 20, 2023

UK-based pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced last week that it has received regulatory...

Company Drug

Alphamab Oncology’s JSKN003 ADC: Promising Preliminary Data in Advanced Solid Tumors

Fineline Cube Nov 17, 2023

Alphamab Oncology (HKG: 9966) has released preliminary data from a Phase I clinical study on...

Policy / Regulatory

Final Results of China’s Round 9 Volume-Based Procurement Tender Announced

Fineline Cube Nov 17, 2023

The National Allied Procurement Office has released the finalized results and tender bid allocations for...

Company Drug

BMS’s Augtyro Receives FDA Approval for ROS1-Positive NSCLC

Fineline Cube Nov 17, 2023

The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS, NYSE: BMY)...

Posts pagination

1 … 442 443 444 … 666

Recent updates

  • Alibaba Health Reports Strong FY2026 Results with 35.2% Profit Growth and Launches Medical LLM “H+”
  • Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration
  • China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations
  • Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma
  • AstraZeneca Reports Positive Phase III VOLGA Interim Results for Imfinzi-Based Combinations in Muscle-Invasive Bladder Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Digital

Alibaba Health Reports Strong FY2026 Results with 35.2% Profit Growth and Launches Medical LLM “H+”

Company Drug

Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Company Drug

Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.